SCHEMBL277919

SCHEMBL277919

C=CC[C](O)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 1/20 0.44
ALDH1A1 P00352 6/20 0.40
HPGD P15428 2/20 0.40
LMNA P02545 1/20 0.40
CES1 P23141 2/20 0.37
MAPK1 P28482 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
CYP3A4 P08684 1/20 0.37
MAPT P10636 1/20 0.37
ALOX15 P16050 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
POLB P06746 1/20 0.37
TSHR P16473 3/20 0.36
CYP2C19 P33261 1/20 0.36
DAO P14920 1/20 0.36
NAPRT Q6XQN6 1/20 0.36
CES2 O00748 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5080711 0.80 AKT1 (0.44) AKT1ALDH1A1HPGDLMNACES1
SCHEMBL3297834 0.80 AKT1 (0.44) AKT1ALDH1A1HPGDLMNACES1
SCHEMBL18585106 0.80 AKT1 (0.44) AKT1ALDH1A1HPGDLMNACES1
SCHEMBL30680 0.78 MAOA (0.48) AKT1ALDH1A1HPGDLMNAPOLB
Water SCHEMBL8670864 0.76 MAOA (0.47) AKT1ALDH1A1HPGDLMNAPOLB
SCHEMBL11214238 0.76 AKT1 (0.41) AKT1ALDH1A1HPGDLMNACES1
Charcoal, Activated SCHEMBL9723289 0.76 MAOA (0.47) AKT1ALDH1A1HPGDLMNAPOLB
SCHEMBL7886735 0.76 AKT1 (0.41) AKT1ALDH1A1HPGDLMNACES1
SCHEMBL367640 0.76 AKT1 (0.58) AKT1ALDH1A1HPGDLMNACES1
SCHEMBL10611184 0.76 ALDH1A1 (0.42) AKT1ALDH1A1HPGDLMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1957127-B1 HYDROPHILIC COATING COMPOSITION FOR URINARY CATHETER DSM IP ASSETS BV (NL) 2018-02-21 EP claimed
US-20140194486-A1 THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2014-07-10 US claimed
US-8133580-B2 Coating composition for a urinary catheter DSM IP ASSETS B.V. (NL) 2012-03-13 US claimed
EP-2315749-A2 NEW THERAPEUTIC AGENTS Cancer Research Technology Limited (GB) 2011-05-04 EP claimed
WO-2009156735-A2 NEW THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2009-12-30 WO claimed
US-20090306244-A1 STERILISATION OF A MEDICAL DEVICE BY IRRADIATION DSM IP ASSETS B.V. (NL) 2009-12-10 US claimed
US-20090155575-A1 COATING COMPOSITION FOR A URINARY CATHETER DSM IP ASSETS B.V. (NL) 2009-06-18 US claimed
EP-2035045-A1 STERILISATION OF A MEDICAL DEVICE BY IRRADIATION DSMIP Assets B.V. (NL) 2009-03-18 EP claimed
EP-1957127-A2 HYDROPHILIC COATING COMPOSITION FOR URINARY CATHETER DSMIP Assets B.V. (NL) 2008-08-20 EP claimed
WO-2007137699-A1 STERILISATION OF A MEDICAL DEVICE BY IRRADIATION DSM IP ASSETS B.V. (NL) 2007-12-06 WO claimed
CN-1044350-A BIPOLAR LIQUID ELECTROSTATIC DEVELOPER DU PONT (US) 1990-08-01 CN claimed
CN-1044349-A Organic compounds containing sulfur as adjuvants for positive electro-static liquid developers DU PONT (US) 1990-08-01 CN claimed
EP-0300526-A2 Antiviral pharmaceutical compositions containing cyclodextrins JANSSEN PHARMACEUTICA N.V. (BE) 1989-01-25 EP claimed
US-4772699-A STABILIZERS FOR POLYPROPYLENE AUSIMONT S.P.A. (IT) 1988-09-20 US claimed
EP-0267439-A2 Alpha-(phenylalkyl) pyridinealkanol derivatives G.D. Searle & Co. (US) 1988-05-18 EP claimed
EP-0229655-A2 Morpholine derivatives containing substituted piperidine groups and use thereof as stabilizers AUSIMONT S.r.l. (IT) 1987-07-22 EP claimed
US-4401817-A ANTIVIRAL AGENTS ELI LILLY AND COMPANY (US) 1983-08-30 US claimed
US-4338329-A COMBATTING RHINOVIRUSES ELI LILLY AND COMPANY (US) 1982-07-06 US claimed
US-4289782-A PARTICULARLY FOR INHIBITING GROWTH OF RHINOVIRUSES ELI LILLY AND COMPANY (US) 1981-09-15 US claimed
US-4230868-A α-Alkyl-α-hydroxybenzyl-substituted 1-sulfonylbenzimidazoles ELI LILLY AND COMPANY (US) 1980-10-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194486-A1 THERAPEUTIC AGENTS TP53, MDM2, TP53BP1 AKT1 188/4885ALDH1A1 2445/4885HPGD 2701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.